10:51 AM EDT, 04/21/2026 (MT Newswires) -- Journey Medical (DERM) secured a contract with a third major group purchasing organization, expanding access to its Emrosi rosacea treatment.

The agreement lifts payer coverage to 85% of people with commercial insurance in the US, up to more than 150 million individuals from 100 million, the company said Tuesday in a statement.

Price: 5.11, Change: -0.09, Percent Change: -1.64

Ämnen i artikeln

Journey Medical

Senast

5,06

1 dag %

−2,50%

1 dag

1 mån

1 år

Marknadsöversikt

1 DAG %

Senast

1 mån